{"id":"cellcept-in-autoimmune-bullous-dermatoses","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)"},{"rate":"10-25","effect":"Leukopenia"},{"rate":"10-20","effect":"Infection (due to immunosuppression)"},{"rate":"5-15","effect":"Anemia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolate mofetil is an immunosuppressant that preferentially targets IMPDH type II, which is predominantly expressed in activated lymphocytes. By depleting guanosine nucleotides required for DNA synthesis, it suppresses T and B cell proliferation without affecting other cell types as severely. In autoimmune bullous dermatoses, this reduces the pathogenic autoantibody production and T cell-mediated inflammation driving blister formation.","oneSentence":"Cellcept (mycophenolate mofetil) selectively inhibits inosine monophosphate dehydrogenase (IMPDH) in T and B lymphocytes, suppressing their proliferation and reducing autoimmune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:19.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune bullous dermatoses (including pemphigus vulgaris, bullous pemphigoid, and related conditions)"}]},"trialDetails":[{"nctId":"NCT02993133","phase":"PHASE3","title":"Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-12","conditions":"Autoimmune Bullous Dermatose","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cellcept® in autoimmune bullous dermatoses","genericName":"Cellcept® in autoimmune bullous dermatoses","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cellcept (mycophenolate mofetil) selectively inhibits inosine monophosphate dehydrogenase (IMPDH) in T and B lymphocytes, suppressing their proliferation and reducing autoimmune responses. Used for Autoimmune bullous dermatoses (including pemphigus vulgaris, bullous pemphigoid, and related conditions).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}